Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of rocatinlimab in adults with prurigo nodularis inadequately controlled by or unsuitable for local therapy
CTR20243637Phase 3Terminated
- Sponsor
- Amgen
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of rocatinlimab in prurigo nodularis (PN), sponsored by Amgen. Started Sep 2024; status: terminated.
02
Drugs
rocatinlimab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on CTR20243637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243637.